Selitrectinib

Description: Selitrectinib (LOXO-195) is a potent and selective inhibitor of receptor tyrosine kinases TRK (TrkA and TrkC) with IC50 values of 0.6 nM and <2.5 nM, respectively. Target: Trk receptor. Smiles: [H][C@]12CCCN1c1ccn3ncc(C(=O)N[C@H](C)CCc4ncc(F)cc24)c3n1. References: Drilon A , Nagasubramanian R , Blake J F , et al. A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion-Positive Solid Tumors[J]. Cancer Discovery, 2017, 7(9):CD-17-0507.